.jpg)
Dr. Radhika Rajagopalan
Board Member
Radhika has recently retired from the FDA, Center for Drug Evaluation and Research after almost 24 years of service in various capacities. She had served as an Expert Reviewer, held both Team Leader position and interdisciplinary position with in Office of Pharmaceutical Quality (OPQ) – policy office from Life Cycle Products, during the development and implementation of ANDA stability Guidance. Prior to FDA, she spent 7 years with the Pharma R& D having worked for both Warner Lambert – Parke Davis division, as well as Bristol Myers Squibb. She has contributed to writing portions of IND, Supplements, and Phase 3 stages and worked under GMP. Her experience over the years cover Rx, and Rx to OTC switches. Radhika has a Ph.D. in Organic Chemistry from Oklahoma State University and has completed post-doctoral research from the University of Kansas, Lawrence in Bioanalytical Chemistry.
Radhika joined the board of Loudoun Serenity House in 2019 as a Member. She shares the mission to provide safe, supportive and affordable residential services to women striving for their best life, a substance free life, free from dependency on alcohol and drugs.
Radhika joined the board of Loudoun Serenity House in 2019 as a Member. She shares the mission to provide safe, supportive and affordable residential services to women striving for their best life, a substance free life, free from dependency on alcohol and drugs.